Selected Compounds in CuraBase® - Register Now for Full Access!
|
Selected Compounds in CuraBase® - Register Now for Full Access! |
About Contact |
| Home | | Compounds | | Expert Opinion | | Trial Analysis | | Pathways | | Diseases | | Workspace | | TOUR |
 |
|
| SELECTED DRUGS FROM THE CURABASE DATABASE: | |
| Abbot Laboratories: ABT-510, ABT-751, A-176120, ABT-510 | ||
| Abgenix, Inc.: Figitumumab, ABX-EGF | ||
| Adherex Technologies Inc.: ADH-1 | ||
| American Pharmaceutical Partners, Inc.: Abraxane | ||
| Amgen: Panitumumab | ||
| ANTISENSE PHARMA GmbH: AP 12009 | ||
| Antisoma plc: AS1411 | ||
| ARIAD Pharmaceuticals, Inc.: Ridaforolimus | ||
| Arqule, Inc.: ARQ 197 | ||
| AstraZeneca: ZD9331, AZD4877, Arimidex, Iressa, ZD6474, ZD9331 | ||
| Aton Pharma, Inc.: Zolinza | ||
| Bayer Corporation: Telatinib | ||
| Bedford Laboratories: Cladribine | ||
| Berlex Laboratories: Fludarabine | ||
| BiPar Sciences Inc: BSI-201 | ||
| Boehringer Ingelheim Pharma KG: BIBX 1382 | ||
| Bristol-Myers-Squibb: BMS-214662, Cetuximab, BMS-214662, Ixempra, Sprycel | ||
| CanBas Co., Ltd.: CBP501 | ||
| Celator Pharmaceuticals, Inc: CPX-1 | ||
| Celgene Corporation: Amrubicin, RevLimid | ||
| Cell Therapeutics, Inc.: XYOTAX | ||
| Daiichi Pharmaceutical Co., Ltd.: DJ-927 | ||
| Eisai, Inc.: E7070, E7389 | ||
| Eli Lilly and Company: ISIS 3521, Alimta, Gemzar | ||
| Exelixis, Inc.: XL184 | ||
| F. Hoffmann-La Roche Ltd: Erlotinib, Xeloda | ||
| Fresenius AG: Rexomun | ||
| Fujisawa Pharmaceutical Co., Ltd.: romidepsin | ||
| Genentech Inc.: Pertuzumab, Avastin, Herceptin | ||
| Genmab, Inc.: HuMax-EGFr | ||
| Genta, Inc.: Genasense | ||
| Genzyme: Clofarabine | ||
| GlaxoSmithKline: Lapatinib, Navelbine, Votrient | ||
| ImClone Systems Incorporated: Ramucirumab, Cetuximab, Erbitux | ||
| Immunogen Inc.: MLN2704 | ||
| Indena SpA: BAY 59-8862 | ||
| Insititue of Cancer Research, Sutton, UK: ICR62 | ||
| ISIS Pharmaceuticals: Affinitak, ISIS 3521 | ||
| Janssen: Zarnestra | ||
| Keryx Biopharmaceuticals, Inc.: Perifosine | ||
| Matrix Pharmaceuticals, Inc.: Cisplatin-epinephrine gel | ||
| Medarex: Ipilimumab | ||
| MediGene AG: EndoTAG(TM)-1 | ||
| MedImmune, Inc.: Siplizumab | ||
| Merck & Co., Inc.: Dalotuzumab | ||
| Merck KGaA: Cetuximab | ||
| MethylGene Inc: MGCD0103 | ||
| Millenium Pharmaceuticals, Inc.: MLN2704, Bortezomib, Velcade | ||
| MolMed: NGR-hTNF | ||
| Neopharm: LE-SN38 | ||
| Nereus Pharmaceuticals: NPI-0052 | ||
| Nerviano Medical Sciences: PHA-739358 | ||
| Novartis: PKC412, AEE788, Femara, Gleevec, PKC412, RAD001 | ||
| Oncotest GmbH: Omnitarg | ||
| Onyx Pharmaceuticals: Nexavar, ONYX-015 | ||
| OSI Pharmaceuticals, Inc.: CP-724,714, Tarceva | ||
| Oxigene, Inc: Combretastatin A4P | ||
| Pfizer Inc.: CI-1033, CP-724,714, AG2037, CI-1033, Sutent | ||
| Pharmacia Corporation: Camptosar | ||
| PharmaMar USA : Trabectedin | ||
| Plexxicon, Inc.: PLX4032 | ||
| Regeneron Pharmaceuticals: VEGF Trap | ||
| Roche Pharmaceuticals: PLX4032 | ||
| Sanofi-Aventis: RPR109881, Taxotere | ||
| Sanofi-Synthelabo: Eloxatin | ||
| Schering AG: PTK787 | ||
| Schering-Plough: Sarasar | ||
| Seattle Genetics, Inc.: SGN-30 | ||
| Sumitomo Pharmaceutical Co., Ltd.: Calsed | ||
| SuperGen, Inc.: Decitabine, Orathecin | ||
| Synta Pharmaceuticals Corp.: STA-4783 | ||
| Taiho Pharmaceutical Co. Ltd: S-1 | ||
| TopoTarget A/s: Belinostat | ||
| Vion Pharmaceuticals, INC.: Triapine | ||
| Wyeth-Ayerst Research: Torisel | ||
| YM BioSciences Inc.: TheraCIM R3 | ||
| ZERIA Pharmaceuticals: Z-360 | ||
| Ζterna Zentaris Inc.: Perifosine, Neovastat | ||
